Zhejiang Hisun Pharmaceutical Hits Day High with Strong Intraday Performance

Zhejiang Hisun Pharmaceutical Co., Ltd. has shown significant activity today, with the stock rising by 3.26% on July 10, 2026. The stock reached an intraday high of CNY 10.84, reflecting a positive trend in its performance metrics. Over the past month, the company has demonstrated a robust increase of 11.49%, outperforming the China Shanghai Composite, which saw a marginal gain of just 0.07%. In terms of annual performance, Zhejiang Hisun has faced challenges, with a decline of 10.18% over the past year, contrasting sharply with the China Shanghai Composite's gain of 13.86%. However, the year-to-date performance shows a more favorable picture, with the stock up by 8.9%, compared to the composite's modest increase of 0.69%. The company's financial health is underscored by a return on equity (ROE) of 5.96% and a price-to-book ratio of 1.47, indicating an attractive valuation. Additionally, the stock offers a dividend yield of 2.1%, further enhancing its appeal in the pharmaceuticals and biotechnology sector.